Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01933607
Other study ID # 1513-CL-VL-01 SOU UK
Secondary ID
Status Recruiting
Phase N/A
First received March 8, 2013
Last updated October 19, 2015
Start date May 2014
Est. completion date December 2016

Study information

Verified date October 2015
Source Premia Spine
Contact Stephen McGillion, MD
Phone 02380796245
Email Stephen.McGillion@uhs.nhs.uk
Is FDA regulated No
Health authority United Kingdom: Research Ethics Committee
Study type Interventional

Clinical Trial Summary

This Single-Arm Post-Marketing Evaluation will gauge the improvement in function and pain for lumbar spinal stenosis and spondylolisthesis patients with the TOPS System.


Description:

This Single-Arm Post-Marketing Evaluation will gauge the improvement in function and pain for lumbar spinal stenosis and spondylolisthesis patients with the TOPS System. Patients who are scheduled to undergo spinal surgery as part of their medical treatment and comply with the study inclusion/exclusion criteria will be recruited. Patients will undergo standard surgical decompression prior to device implantation. For patients with two or three levels of disease, the TOPS System will be combined with the Versalink Fixation System. All study devices are CE marked.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date December 2016
Est. primary completion date December 2016
Accepts healthy volunteers No
Gender Both
Age group 40 Years to 85 Years
Eligibility Inclusion Criteria:

Any subject meeting the following criteria will be considered for inclusion in this trial.

1. Patients with one or both of the following conditions at a single spinal level between L3 and L5 are eligible for the TOPS™ System:

- Symptomatic monosegmental lumbar spinal stenosis or facet arthrosis

- Degenerative Spondylolisthesis up to and including grade 1

2. At least three (3) months of failed, conservative treatment, including use of anti-inflammatory medications at maximum specified dosage; epidural/facet injections, unless deemed inadvisable due to progressive motor weakness or other evidence of deteriorating condition; rest, heat, electrotherapy/physical therapy;

3. Moderate to Severe narrowing of the lumbar spinal canal identified on CT /MRI scans

4. Age 40-85 years old

5. Lower back pain /sciatica with or without spinal claudication

6. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to the follow-up schedule.

7. VAS leg pain of at least 40/100 at baseline.

8. Oswestry Questionnaire score of at least 40/100 at baseline

Exclusion Criteria:

Patients who meet any of the following conditions or criteria are excluded from this study:

1. Primary diagnosis of discogenic back pain at the TOPS System level

2. Back or non-radicular leg pain of unknown etiology at the TOPS System level

3. Lytic spondylolisthesis at the TOPS System level

4. More than one (1) motion segment involved in the degenerative pathology to the extent that justifies its inclusion in the surgical procedure, unless a decompression alone can be done at that level without compromising stability.

5. Known allergy to titanium and/or polyurethane

6. Prior surgery at any lumbar vertebral level.

7. Supplemental interbody support required (e.g., VBRs, or fusion cages) at the TOPS System level

8. Clinically compromised vertebral bodies at the affected level(s) due to any traumatic, neoplastic, metabolic or infectious pathology.

9. Deformity of the spine that would compromise the implant, e.g. scoliosis of greater than ten (10) degrees

10. Morbid obesity (a body mass index > 40) or a weight more than 100 lbs. over ideal body weight.

11. DEXA bone density T score equal to or lower than - 2.0

12. Paget's disease, osteomalacia, osteogenesis imperfecta, thyroid and/or parathyroid gland disorder and/or any other metabolic bone disease.

13. Active infection - systemic or local

14. AIDS, HIV, or active hepatitis

15. Rheumatoid arthritis or other autoimmune disease.

16. Tuberculosis active or in the past 3 years.

17. Active malignancy: A patient with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no clinical signs or symptoms of the malignancy for at least 5 years.

18. Medical conditions requiring treatment with any drugs known to potentially interfere with bone/soft tissue healing

19. Pregnant or interested in becoming pregnant in the next 3 years.

20. Current chemical/alcohol dependency or psychosocial disturbance.

21. Cauda equina syndrome or neurogenic bowel/bladder dysfunction

22. Severe arterial insufficiency of the legs, peripheral vascular disease

23. Sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip

24. Unremitting pain in any spinal position

25. Significant peripheral neuropathy

26. Immunologically suppressed, received steroids > 1 month out of the past year aa. Insulin-dependent diabetes mellitus bb. Currently taking anticoagulants other than aspirin (e.g., Plavix) cc. Life expectancy less than 3 years dd. Waddell signs > 3 ee. Currently involved in active spinal litigation ff. Subject is incarcerated

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
TOPS System
TOPS™ System Post Marketing Study To Evaluate The Safety And Effectiveness Of TOPS™ in the Lumbar Spine

Locations

Country Name City State
United Kingdom University Hospital Southampton NHS Foundation Trust Southampton

Sponsors (1)

Lead Sponsor Collaborator
Premia Spine

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary VAS (Visual Analog Score) Pain assessment 2 YEARS No
Secondary SF-36 (Short-Form) Quality of life 2 YEARS No
See also
  Status Clinical Trial Phase
Completed NCT06290908 - RPE-P/TLIF for Lumbar Spinal Stenosis With Instability
Withdrawn NCT03223701 - Efficacy of Using Solum IV and BMC With GFC in TLIF Phase 4
Recruiting NCT03883022 - Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery N/A
Completed NCT02902380 - The Effect of Dexmedetomidine on Neuroendocrine Stress Hormone Release and Heart Rate Variability in Patients Undergoing Major Spinal Surgery N/A
Not yet recruiting NCT06024785 - Vertebropexy - Randomized-controlled Trial N/A
Not yet recruiting NCT06000319 - Natural Matrix Protein™ (NMP™) Fibers in Cervical and Lumbar Interbody Fusion
Completed NCT02558621 - New Robotic Assistance System for Spinal Fusion Surgery N/A
Completed NCT02454400 - Pre-surgery Physiotherapy for Patients With Specific Low Back Pain N/A
Completed NCT01377623 - Pilot Study on the Effect of Dexmedetomidine on Inflammatory Responses in Patients Undergoing Lumbar Spinal Fusion N/A
Terminated NCT00974623 - Bone Graft Materials Observational Registry N/A
Completed NCT00996073 - Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion Phase 2
Completed NCT00320619 - Epsilon-Aminocaproaic Acid to Reduce the Need for Blood Transfusions During and Following Spine Surgery N/A
Completed NCT00022776 - Surgical Versus Nonsurgical Treatment for Spinal Stenosis Phase 3
Completed NCT06060821 - Validity and Reliability of the 2-minute Step Test in Patients With Lumbar Spinal Stenosis
Recruiting NCT04552145 - Physical Therapy vs Surgical Decompression for Lumbar Spinal Stenosis N/A
Active, not recruiting NCT04379921 - Improving Spine Surgical Care With Real-Time Objective Patient Tracking Using the Apple Watch N/A
Withdrawn NCT04315090 - Post-surgical Outcomes Measure Using the ERAS Protocol for Posterior Cervical Decompression and Fusion
Completed NCT04591249 - Physical Activity Intervention for Patients Following Lumbar Spine Surgery N/A
Recruiting NCT04601363 - Personalized Spine Study Group (PSSG) Registry
Completed NCT04193488 - Mid-Transverse Process to Pleural (MTP) Block and Erector Spinal Plan (ESP) Block in Spinal Surgery N/A